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OBJECTIVE— To evaluate ethnic differences in medication concerns (e.g., side effects and
costs) that may contribute to ethnic differences in the adoption of and adherence to type 2
diabetes treatments.
RESEARCH DESIGN ANDMETHODS— We conducted face-to-face interviews from
May 2004 to May 2006 with type 2 diabetic patients 18 years of age (N  676; 25% Latino,
34% non-Hispanic Caucasian, and 41% non-Hispanic African American) attending Chicago-
area clinics. Primary outcomes of interest were concerns regarding medications and willingness
to take additional medications.
RESULTS— Latinos and African Americans had higher A1C levels than Caucasians (7.69 and
7.54% vs. 7.18%, respectively; P 0.01). Latinos and African Americans were more likely than
Caucasians to worry about drug side effects (66 and 49% vs. 39%, respectively) and medication
dependency (65 and 52% vs. 39%, respectively; both P  0.01). Ethnic minorities were also
more likely to report reluctance to adding medications to their regimen (Latino 12%, African
American 18%, and Caucasian 7%; P 0.01). In analyses adjusted for demographics, income,
education, and diabetes duration, current report of pain/discomfort with pills (odds ratio 2.43
[95% CI 1.39–4.27]), concern regarding disruption of daily routine (1.97 [1.14–3.42]), and
African American ethnicity (2.48 [1.32–4.69]) emerged as major predictors of expressed reluc-
tance to adding medications.
CONCLUSIONS— Latinos and African Americans had significantly more concerns regard-
ing the quality-of-life effects of diabetes-related medications than Caucasians. Whether these
medication concerns contribute significantly to differences in treatment adoption and disparities
in care deserves further exploration.
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T ype 2 diabetic patients of racial/ethnic minorities experience signifi-cantly higher rates of diabetes-
related complications than non-Hispanic
Caucasians. In population-based studies,
non-Hispanic African Americans have
rates of renal disease, blindness, amputa-
tions, and amputation-related mortality
two to four times greater than those of
Caucasians (1–3). Similarly, Latinos have
higher rates of renal disease and retinop-
athy than Caucasians (1,2,4,5). African
American patients have age-adjusted dia-
betes mortality rates that are approxi-
mately twice those of Caucasians (6). The
elimination of such health disparities is a
major goal of the U.S. preventive health
agenda (7).
Efforts to reduce the burden of diabe-
tes complications have focused on im-
proving the delivery of comprehensive
diabetes care while simultaneously ad-
dressing control of blood glucose, blood
pressure, and cholesterol. Modern dia-
betes care requires greater use of medi-
ca t ions and a s tandard form of
polypharmacy (8–10). Whereas there is
some evidence that more patients with di-
abetes are adopting comprehensive dia-
betes care (11), many recent studies
continue to show that large proportions of
patients with diabetes continue to have
poor glycemic (20%), blood pressure
(33%), and cholesterol (40%) control
(12). Patients’ concerns regarding the
burdens of life with medications may be
key factors to determining patients’ will-
ingness or unwillingness to adopt multi-
ple medications; an unwillingness to
adopt medications may be grounded in
legitimate concerns. Patients’ level of
adoption of multiple medications may, in
turn, influence the intensity of risk factor
control for the general population and for
racial/ethnic minorities. In support of this
conjecture, a recent study has reported
that racial/ethnic differences in medica-
tion adherence are among the most signif-
i cant independent predic tors o f
disparities in glycemic control (13).
Whereas patient concerns regarding
the burdens of medications may be a key
determinant of both the intensity of dia-
betes care for the general population and
disparities in care, few studies have di-
rectly examined and quantified patient
concerns regarding the burdens of daily
diabetes medications across racial/ethnic
groups (14). These concerns may system-
atically differ by race/ethnicity and may
be associated with differential willingness
to adopt more medications. We set out to
determine whether there are racial/ethnic
differences in medication concerns and
the willingness to adopt more medica-
tions among a sample of adults with type
2 diabetes living in the Chicago area.
RESEARCH DESIGN AND
METHODS— From May 2004 to May
2006, we conducted face-to-face inter-
views with diabetic patients aged 18
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years attending clinics affiliated with an
academic medical center (University of
Chicago, Chicago, IL) or physician offices
affiliated with a suburban hospital (Mac-
Neal Hospital, Berwyn, IL). Before con-
ducting the study, we knew that patients
attending the University of Chicago were
predominately African American,
whereas patients attending MacNeal Hos-
pital were mainly Latino and Caucasian.
To achieve an ethnically diverse study
population, we planned for balanced re-
cruitment from the two sites. We identi-
fied patients using electronic billing data
provided by the clinics. Patients were in-
cluded if they had an ICD-9 billing code
of 250.xx in the past year and were 18
years of age. Physicians at each clinic ap-
proved which patients we were permitted
to contact. We excluded patients with
type 1 diabetes, as well as those who had
dementia during telephone recruitment.
Additional patients were excluded if they
scored 17 points on the Mini-Mental
State Examination (15) during in-person
interviews. Potential subjects were sent
study recruitment letters in random or-
der. Letters were followed by a telephone
call. We successfully contacted 2,990 pa-
tients, 2,398 of whom were determined
eligible for the study. A total of 910 pa-
tients (38% of eligible subjects) scheduled
interviews, and 701 patients (29% of eli-
gible subjects) completed interviews. The
average age and sex distributions of sub-
jects who completed interviews did not
differ from those of other eligible subjects.
For the purposes of this analysis, we
focused on the 676 patients who identi-
fied themselves as non-Hispanic African
American, non-Hispanic Caucasian, or
Latino. To determine race/ethnicity, we
separately asked patients to identify their
race (e.g., African American, Caucasian,
Asian, Native American) and to identify
themselves as Hispanic, Latino, or Span-
ish. Interviews took approximately 1 h
and were conducted by trained interview-
ers in English or Spanish. All Spanish in-
terview materials were professionally
translated and back translated. The over-
all survey included an in-depth examina-
tion of health state utilities related to
diabetes treatments and complications
not included in this analysis (16,17).
For the purposes of this analysis, we
focused on the responses to questions re-
garding current and future medications.
The concepts included in the section of
medication concerns were partially
drawn from the existing literature (18,19)
and were influenced by our prior qualita-
tive research with older diabetic patients
(20). New questions were developed and
revised in an iterative fashion by the in-
vestigative team with input from pilot
testing with patients. This section in-
cluded statements regarding concerns
about current medications such as anxiety
about side effects, fear of dependency on
medications, need for help taking medi-
cations, concerns regarding medication
costs, and reports of pain or discomfort
related to medication taking. In a similar
question format, patients were also asked
about the implication of changes to their
medication regimen for their daily routine
and worries about their health. These
statements referred to patients’ percep-
tions of their overall medication regimen
and not to their diabetes-specific medica-
tion regimen. Responses to these state-
ments were recorded on a five-point
Likert scale (“agree strongly,” “agree
slightly,” “neither agree nor disagree,” “dis-
agree slightly,” and “disagree strongly”).
These questions were accompanied
by a series of questions regarding their
willingness to adopt future changes in
treatment regimens. Patients were specif-
ically asked whether they would be will-
ing to take additional medications if told
by their physician that such a change in
their treatment regimen would be benefi-
cial. Among patients currently not taking
insulin, the same question was asked re-
garding the potential addition of insulin.
Responses were recorded as “Yes,” “No,”
or “Don’t know.” These questions were
followed by a series of statements regard-
ing potential concerns regarding the
meaning and consequence of changes in
medications.
We also asked patients a variety of
questions regarding their health-related
quality of life (12-item Short-Form Health
Survey, Version 2 [21]), functional status,
current medications, and diabetes-related
complications. We examined medical
records for additional data on comorbidi-
ties (Charlson Comorbidity Index [22])
and current risk factor levels. To assess
the reliability of chart abstraction, we per-
formed a 10% re-review. The intraclass
correlation coefficients for A1C, systolic
blood pressure, and LDL cholesterol were
0.96, 0.81, and 0.91, respectively. The 
statistic for micro- and cardiovascular
complications of diabetes was 0.79. These
statistics indicate moderate-to-high inter-
rater reliability.
Statistical analysis
All analyses were performed using SAS
statistical software (Release 8.1; SAS Insti-
tute, Cary, NC). The major outcomes of
interest were 1) concerns regarding med-
ications and 2) reluctance to add more
medications or insulin; the major predic-
tor of interest was race/ethnicity. For
statements describing concerns for cur-
rent and future medications, we dichoto-
mized Likert scale responses by grouping
responses of “Agree somewhat” and
“Agree strongly” together. For questions
regarding willingness to take additional
medications, we dichotomized responses
into “No” and all other responses. In un-
adjusted analyses, we compared these
proportions using the 2 test. For ad-
justed analyses, we used logistic regres-
sion. In the adjusted analyses, we
accounted for covariates such as age,
sex, education, income, and duration of
diabetes.
We also examined the interrelation-
ship of concerns regarding medications
and reluctance to add more medications
or insulin. For these analyses, the main
outcome of interest was reluctance to add
more medications. As described above,
we first performed unadjusted analyses
examining the relationship between each
of the concerns for medications and reluc-
tance to add more medications. We then
constructed a multivariable logistic re-
gression model, first considering vari-
ables significantly associated with
outcomes in univariate analysis, followed
by a search for collinear terms. With this
preliminary model, ethnicity was then
incorporated and evaluated for its effects
as a confounder of medication-concern
variables.
The study protocol was approved by
the University of Chicago and MacNeal
Hospital Institutional Review Boards and
found to be in compliance with human
subject protection and Health Insurance
Portability and Accountability Act
(HIPAA) regulations.
RESULTS— We interviewed 676 pa-
tients who identified themselves as Cau-
casian (34%), African American (41%), or
Latino (25%) (Table 1). Latino patients
were significantly younger (mean age 55
years vs. 65 years for African Americans
and Caucasians; P 0.01), more likely to
have been born outside the U.S. (64% vs.
1 and 7%, respectively; P  0.01), and
less likely to have completed high school
(50% vs. 73 and 84%, respectively; P 
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0.01). Half of the interviews with Latinos
were conducted in Spanish. The overall
study population was well insured with
over half of the patients having some form
of private insurance and 90% of pa-
tients having a prescription drug plan.
There was no significant difference in
the mean duration of diabetes across eth-
nic groups (9–10 years). However, there
were differences in the prevalence of co-
morbid conditions or complications
across ethnic groups. Latinos had less
self-reported hypertension than African
Americans and Caucasians, but there was
no difference in prevalence of hypercho-
lesterolemia. African Americans had
higher rates of self-reported diabetes
complications such as eye disease, heart
disease, and stroke, whereas Latinos had
the lowest rates. For overall health status,
Latinos had higher mean physical compo-
nent summary scores than the other eth-
nic groups but lower mental component
summary scores.
Mean A1C levels were higher for Af-
rican Americans (7.54%) and Latinos
(7.69%) than for Caucasians (7.18%)
(P  0.01); consistent with these differ-
ences, lower proportions of African
Americans (41%) and Latinos (47%) had
A1C levels 7% than of Caucasians
(55%) (P 0.01). With regard to choles-
terol control, Latinos also had the highest
mean LDL cholesterol levels (102 vs. 95
mg/dl) and the lowest proportion of pa-
tients with LDL cholesterol levels 100
Table 1—Demographics and clinical characteristics by race/ethnicity among adults with type 2 diabetes in Chicago-area clinics, 2004–2006
Caucasian
African
American Latino P*
n 230 279 167
Age (years) 65  13 65  13 55  13 0.0001
Male 50 32 48 0.0001
Born outside the U.S. 7 1 64 0.0001
Interview conducted in Spanish 0 0 51 0.0001
High school graduate 84 73 50 0.0001
Health insurance
Private 75 55 69 0.0001
Medicare 50 58 22 0.0001
Medicaid 8 29 16 0.0001
Prescription drug plan 90 93 92 0.6301
Annual income 10,000 USD 11 29 13 0.0001
Duration of diabetes (years) 10  9 10  9 9  7 0.4631
Self-reported comorbid conditions or complications
Hypertension 72 86 57 0.0001
Hypercholesterolemia 70 62 63 0.1322
Diabetic eye disease 13 22 25 0.0081
Diabetic kidney disease 6 8 10 0.3259
Foot disease (peripheral neuropathy and amputation) 56 54 45 0.0796
Heart disease 33 34 22 0.0258
Stroke 9 16 4 0.0004
SF-12
PCS 42  12 41  12 47  10 0.0001
MCS 51  11 51  11 47  11 0.0004
Risk factor levels†
A1C (%) 7.18  1.45 7.54  1.59 7.69  1.78 0.0057
A1C 7% 55 41 47 0.0057
LDL cholesterol (mg/dl) 93  35 96  32 102  34 0.0090
LDL cholesterol 100 mg/dl 65 61 56 0.1962
Systolic blood pressure (mmHg) 130  16 136  18 126  17 0.0001
Systolic blood pressure 130 mmHg 47 32 54 0.0001
Number of medications‡§ 7  4 7  3 5  3 0.0002
Mean number of diabetes-related medications‡ 4  2 4  2 3  2 0.0001
Glucose lowering therapy‡
Diet alone 23 19 14 0.0014
Oral medications alone 56 55 68
Insulin and oral medications 8 16 5
Insulin alone 13 11 13
Aspirin‡ 47 43 24 0.0001
Cholesterol lowering drug‡ 68 53 51 0.0006
Data are means  SD or % unless otherwise indicated. *Differences in means were assessed with the Wilcoxon’s rank-sum test; differences in proportions were
assessed with the 2 test. †Abstracted from medical records. ‡Based on patient self-report. §The most common nondiabetes-related medications included multi-
vitamins, proton-pump inhibitors, calcium supplementation, and thyroid replacement therapy. MCS, mental component summary; PCS, physical component
summary; SF-12, 12-item Short-Form Health Survey.
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mg/dl (56 vs. 63%) of the three racial/
ethnic groups (P 0.01). The picture was
reversed in the case of blood pressure
control in that Latinos had the lowest
mean systolic blood pressure levels (126
mg/dl) of the three groups, whereas Afri-
can Americans had the highest (136 mg/
dl) (P  0.01).
Consistent with our findings related
to risk factor levels, Latinos had the lowest
use of medications among the three racial/
ethnic groups: the lowest mean number
of both total medications and diabetes-
related medications (three vs. four medi-
cations for African Americans and
Caucasians; P 0.01). In terms of inten-
sity of glucose control regimen, Latinos
also had the lowest percentage of insulin
use (18%), whereas African Americans
had the highest use of insulin (27%) (P
0.01). Similarly, Latinos had the lowest
percentage of aspirin prophylaxis use (24
vs. 47% for Caucasians) and cholesterol-
lowering drug use (51 vs. 68% for Cauca-
sians; both P  0.01). Frequently used
nondiabetes medications included multi-
vitamins, proton-pump inhibitors, cal-
cium supplementation, and thyroid
replacement therapy.
In direct questions regarding con-
cerns for medications, both African
Americans and Latinos had significantly
more concerns about various elements of
medication-taking than Caucasians (Ta-
ble 2). They were more likely to say that
they worried about side effects (African
Americans 49% and Latinos 66% vs. Cau-
casians 39%), development of depen-
dency on medications (52% and 65% vs.
39%, respectively), and the potential
harms of generic substitutes (35 and 26%
vs. 13%, respectively; all P  0.01).
Three-quarters of Latinos had concerns
about the costs of medications compared
with one-half of African Americans and
Caucasians (P 0.01). With regard to the
implications of future changes to medica-
tion regimens, African Americans and
Latinos were also more likely to report
that changes in their medication regimen
would represent a disruption in their
daily routine and would raise concerns
about their health.
When we directly queried patients
about their willingness to adopt more
medications, we found significant differ-
ences across racial/ethnic groups. More
African Americans (18%) and Latinos
(12%) than Caucasians would be op-
posed to the addition of more medica-
tions if recommended by their physician
(7%) (P 0.01), although the majority of
patients in all groups would accept such
changes in their medications. When
asked about the possibility of adding in-
sulin (among those not using insulin), the
proportion of patients opposed to such a
change was larger than the proportion op-
posed to the general addition of more
medications. As observed with the prior
question, larger proportions of African
Americans (26%) and Latinos (22%) than
Caucasians (17%) were opposed to the
addition of insulin to their regimens (P
0.09), although this difference did not
reach statistical significance.
The majority of these unadjusted ra-
cial/ethnic differences in medication con-
cerns were attenuated by adjustment for
socioeconomic, demographic, and clini-
cal covariates but remained significant
(Table 3). For example, the association
between race/ethnicity and side effect
concerns became less pronounced in ad-
justed analysis (for Latinos, unadjusted odds
ratio (OR) 3.00 [95% CI 1.98–4.55]3 ad-
justed OR 2.92 [1.83–4.64]). With re-
gard to responses to questions regarding
the addition of more medications, African
Americans remained significantly more
likely to express a reluctance to add new
medications than Caucasians (unadjusted
OR 3.05 [1.66 –5.61] 3 adjusted OR
2.53 [1.35–4.72]) even after adjustment
for socioeconomic, demographic, and
clinical covariates. Latino-Caucasian dif-
Table 2—Differences in medication concerns and perceptions of future medications by race/ethnicity among adults with type 2 diabetes in
Chicago-area clinics, 2004–2006*
Caucasian
African
American Latino P
n 230 279 167
Statements reflecting medication concerns (proportion responding affirmatively)
I worry about side effects from my medications. 39 49 66 0.0001
I worry about becoming dependent on my medications. 39 52 65 0.0001
I worry about the expense of my medications or glucose-monitoring supplies. 52 51 71 0.0001
I have problems with my prescription drug plan. 24 24 29 0.4962
I sometimes have difficulty remembering to take my medications. 34 34 39 0.5357
I could use another person’s help taking my medications. 15 19 23 0.1570
I find taking my pills unpleasant or painful. 12 17 17 0.2819
I find taking my insulin unpleasant or painful. 57 (39) 87 (40) 32 (50) 0.5466
If my doctor asked me to change my medication regimen, it would disrupt
my daily routine. 14 18 27 0.0041
If my doctor asked me to change my medication regimen, it would make me
worry more about my health. 22 41 57 0.0001
I worry about switching from name-brand to generic drugs. 13 35 26 0.0001
Willingness to take more medications or insulin (proportion responding “No”)
If your doctor told you that you would benefit from taking more medications,
would you be willing to take more? 7 18 12 0.0008
If your doctor told you that you would benefit from taking insulin, would
you be willing to take insulin? 173 (17) 191 (26) 135 (22) 0.0940
Data are % or n (%) unless otherwise indicated. *All analyses performed using 2tests. Original responses to questions regarding medication concerns were originally
on a Likert scale (“agree strongly,” “agree slightly,” “neither agree nor disagree,” “disagree slightly,” and “disagree strongly”). Original responses to questions regarding
willingness to take more medications were “Yes,” “No,” and “Don’t know.”
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ferences in opinion were borderline in
significance in unadjusted analysis (1.95
[0.97–3.93]) and became clearly non-
significant (1.48 [0.69 –3.15]) when
accounting for covariates.
In our comprehensive analysis of pre-
dictors of a reluctance to add medica-
tions, we found that concerns about
growing dependent on medications, re-
port of unpleasant or painful experience
with medications, anticipated disruption
of daily routine, concerns regarding
health if faced with medication changes,
and concerns over switches from brand-
name to generic drugs were all signifi-
cantly associated with a reluctance to add
more medications (all P 0.01). The pa-
tient’s physical health status, current
number of medications, and current
number of diabetes-related medications
were not significantly associated with a
reluctance to add more medications.
Higher mental health status was associ-
ated with a lower likelihood of opposing
additional medications (P  0.01). After
identification and exclusion of collinear
variables, the final model of a reluctance
to add more medications included report
of unpleasant or painful experience with
medications (OR 2.43 [95% CI 1.39 –
4.27]; P  0.01) and anticipated disrup-
tion of daily routine (1.97 [1.14–3.42];
P  0.02). African American race re-
mained a significant predictor of reluc-
tance to add more medications even
within the fully adjusted model (2.48
[1.32–4.69]; P  0.01).
CONCLUSIONS— Our study pro-
vides valuable insights into how concerns
regarding quality of life with medications
and the willingness to adopt more medi-
cations vary across type 2 diabetic pa-
tients of various racial/ethnic groups.
Over one-half of racial/ethnic minority
patients in our sample expressed con-
cerns regarding side effects of medica-
tions and the development of possible
dependency on medications, in compari-
son with over one-third of Caucasian re-
spondents. Similarly, approximately one-
half of minority patients would be
concerned about their health as a result of
changes in medication regimens in com-
parison with 22% of Caucasian patients.
Latinos and African Americans were also
more likely to voice reluctance to adding
medications. In adjusted analyses, this
was only found to be significant for Afri-
can Americans. Patients who expressed a
concern regarding the use of medications
were more likely to express reluctance to
adding medications.
Our findings have implications for
the field of health disparities in diabetes
care. The basic finding of ethnic differ-
ences in concerns regarding life with
medications suggests that the everyday
experiences of living with diabetes treat-
ments are, on average, experienced differ-
ently by ethnic groups. These differences
in medication concerns may contribute to
differences in perceived quality of life re-
lated to diabetes (23). Ethnic differences
in perception will require additional
study to determine their origins and to
clarify their implications for long-term
treatment adoption and disparities in
care.
It is important to note that many of
the concerns and attitudes related to med-
ications were shared among all patients.
Patients of ethnic minorities were more
likely to express concerns regarding cur-
rent and future medications, but many
Caucasian patients also shared these con-
cerns. Concerns regarding the physical
and logistical burdens of managing mul-
tiple medications were quite prevalent
throughout the population and are clearly
important to acknowledge with patients
before intensifying or altering medication
regimens. We found that the experience
of pain or discomfort with the use of cur-
rent oral medications was an independent
predictor of reluctance to add more med-
ications. It should be noted that the ma-
jority of patients within each racial/ethnic
subgroup were willing to take additional
medication, including insulin, if advised
to do so by their health care providers.
These results are important reminders
that it is important for providers to ap-
proach patients as individuals and elicit
concerns about current and future medi-
cations from patients irrespective of race/
e thnic i ty . I t may be poss ib le to
acknowledge medication concerns while
also intensifying diabetes care through a
shared decision-making approach to
treatment decisions (24).
There are some limitations to this
study. Our recruitment rate was low,
which is likely related to our attempt to
recruit patients irrespective of frequency
of prior visits to a physician. We speculate
that nonrespondents were less frequent
attendees of clinic and potentially less ad-
herent to medical therapies than respon-
dents. If that is the case, our findings
likely underestimate the level of concern
about life with medications among pa-
tients with diabetes. A related limitation
Table 3—Adjusted analyses of concerns about medications by race/ethnicity, adjusted comparisons in adults with type 2 diabetes from
Chicago-area clinics, 2004–2006*
African American
vs. Caucasian
Latino vs.
Caucasian
Statements reflecting medication concerns (likelihood of responding affirmatively)
I worry about side effects from my medications. 1.32 (0.91–1.92) 2.92 (1.83–4.64)
I worry about becoming dependent on my medications. 1.57 (1.09–2.28) 2.90 (1.83–4.58)
I worry about the expense of my medications or glucose-monitoring supplies. 0.93 (0.64–1.34) 1.84 (1.16–2.93)
If my doctor asked me to change my medication regimen, it would disrupt my daily routine. 1.24 (0.75–2.05) 1.78 (1.01–3.12)
If my doctor asked me to change my medication regimen, it would make me worry more
about my health. 2.29 (1.52–3.45) 3.98 (2.46–6.44)
I worry about switching from name brand to generic drugs. 3.29 (2.06–5.26) 2.12 (1.21–3.73)
Willingness to take more medications or insulin (likelihood of responding “No”)
If your doctor told you that you would benefit from taking more medications, would you be
willing to take more? 2.53 (1.35–4.72) 1.48 (0.69–3.15)
If your doctor told you that you would benefit from taking insulin, would you be willing to
take insulin? 1.59 (0.94–2.70) 1.15 (0.60–2.21)
Data are OR (95% CI). *Each logistic regression model adjusted for sex, education (high school graduate), income (10,000 USD/year), and duration of diabetes.
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of our study is that the views of the pa-
tients whom we surveyed may not be rep-
resentative of all patients with diabetes.
The surveyed patients all had physicians
that granted us permission to recruit
them; the majority of subjects had health
insurance and prescription drug cover-
age. In addition, our Spanish-speaking
Latino patients all saw physicians who
spoke Spanish. Given known disparities
in insurance coverage and access to pro-
viders, it is likely that the degree of health
disparities in this sample and the extent of
racial/ethnic differences in responses to
questions might be less pronounced than
in a population-based study. Nonethe-
less, we still found important disparities
in risk factor control and important dif-
ferences in medication concerns. It is also
important to recognize that the ethnic
group assignment in our sample reflects
the specific ethnic mix of Chicago neigh-
borhoods that composed our clinical
sites. The makeup of the same ethnic
group categories may differ in other parts
of the city, state, and country. Our study
findings also reflect the views of patients
before the publication of reports regard-
ing the potential risks associated with
very intensive glucose control. Current
concerns about quality of life with diabe-
tes-related medications may be even more
widespread than we have found.
Our study provides insights into how
reported concerns regarding diabetes-
related medications vary across racial/
ethnic groups. However, it remains
unclear whether these concerns and per-
ceptions regarding medications are at the
root of observed disparities in diabetes
care and outcomes (25). Longitudinal
studies that help to test the association
between medication concerns with inter-
mediate outcomes after adjusting for dia-
betes severity will be valuable to
addressing this critical question in diabe-
tes health disparities research.
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